Daniel J DeAngelo
Dana-Farber Cancer Institute, Boston, MA · Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel J DeAngelo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:55 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT04817761 · SPARK-ALL: Calaspargase Pegol in Adults With ALLInstitut de Recherches Internationales Servier · terminated · Acute Lymphoblastic Leukemia · principal investigator
- Ph3NCT03616470 · Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid LeukemiaGlycoMimetics Incorporated · terminated · Acute Myeloid Leukemia · principal investigator
- Ph2NCT00136409 · A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)Dana-Farber Cancer Institute · completed · Myelofibrosis, Myeloid Metaplasia, Agnogenic Myeloid Metaplasia · principal investigator
- Ph1NCT00136422 · Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous LeukemiaDana-Farber Cancer Institute · completed · Acute Myelogenous Leukemia, Myelodysplasia · principal investigator
- Ph2NCT00136435 · A Study in Adults With Untreated Acute Lymphoblastic LeukemiaDana-Farber Cancer Institute · completed · Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT00130702 · Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaDana-Farber Cancer Institute · completed · Myelogenous Leukemia, Acute · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Career-Enh-ProgP50CA298970 · NCI · DANA-FARBER CANCER INST · fiscal years 2026 · $87,451 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical Shared ResourceP01CA066996 · NCI · DANA-FARBER CANCER INST · fiscal years 2025 to 2026 · $100,287 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:55 UTC. The ranking covers the 200 most relevant of 93 PubMed records, and a shared surname and initials can bring in a namesake. All 93 on PubMed
- 1,249 citationsRCR 38.4
- 1,127 citationsRCR 36.3
- A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.N Engl J Med · 2013903 citationsRCR 24.7
- 731 citationsRCR 37.6
- 558 citationsRCR 10.9
- 492 citationsRCR 18.4
- 423 citationsRCR 9.4
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.N Engl J Med · 2019376 citationsRCR 13.6
- 298 citationsRCR 11.8
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.Leukemia · 2015283 citationsRCR 8.0